SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study

NCT07417241 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
HER2-positive Breast Cancer

Interventions

DRUG: SHR-A1811
DRUG: Pyrotinib
DRUG: Capecitabine
DRUG: T-DXd

Sponsor

Peking University Cancer Hospital & Institute